Incyte Corporation Total Liabilities
Incyte Corporation total liabilities. Based on the latest financial reports, Incyte Corporation (INCY) has total liabilities worth $1.53 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check INCY asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Incyte Corporation (1993–2025)
Total liabilities of Incyte Corporation from 1993 to 2025. This chart illustrates how Incyte Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Incyte Corporation to see how much of total assets are deployed in long-term investments.
Incyte Corporation Competitors by Total Liabilities
The table below lists competitors of Incyte Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
GE HEALTHCARE TECH.INC.
F:L0T
|
Germany | €26.23 Billion |
|
Compagnie Generale des Etablissements Michelin SCA
PA:ML
|
France | €16.94 Billion |
|
Fresnillo plc
F:FNL
|
Germany | €2.20 Billion |
|
Adani Green Energy Limited
NSE:ADANIGREEN
|
India | Rs1.14 Trillion |
|
S.F. Holding Co. Ltd
SHE:002352
|
China | CN¥108.95 Billion |
|
Tata Steel Limited
NSE:TATASTEEL
|
India | Rs-1.04 Trillion |
|
Corpay Inc
NYSE:CPAY
|
USA | $22.19 Billion |
|
CoreWeave, Inc. Class A Common Stock
NASDAQ:CRWV
|
USA | $50.81 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Incyte Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Incyte Corporation.
Liquidity & Leverage Metrics
Incyte Corporation Total Liabilities Ratios Explained
Incyte Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Incyte Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Incyte Corporation (1993–2025)
The table below shows the annual total liabilities of Incyte Corporation from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.80 Billion | -9.68% |
| 2024-12-31 | $2.00 Billion | +25.40% |
| 2023-12-31 | $1.59 Billion | +8.25% |
| 2022-12-31 | $1.47 Billion | +26.43% |
| 2021-12-31 | $1.16 Billion | +22.50% |
| 2020-12-31 | $949.65 Million | +14.64% |
| 2019-12-31 | $828.34 Million | +15.08% |
| 2018-12-31 | $719.79 Million | +7.12% |
| 2017-12-31 | $671.95 Million | -44.88% |
| 2016-12-31 | $1.22 Billion | +45.78% |
| 2015-12-31 | $836.28 Million | -4.76% |
| 2014-12-31 | $878.11 Million | +6.74% |
| 2013-12-31 | $822.68 Million | +62.78% |
| 2012-12-31 | $505.38 Million | -9.11% |
| 2011-12-31 | $556.04 Million | -3.84% |
| 2010-12-31 | $578.23 Million | -29.03% |
| 2009-12-31 | $814.77 Million | +79.81% |
| 2008-12-31 | $453.14 Million | +4.12% |
| 2007-12-31 | $435.21 Million | -0.75% |
| 2006-12-31 | $438.51 Million | +11.44% |
| 2005-12-31 | $393.50 Million | -10.24% |
| 2004-12-31 | $438.40 Million | +94.66% |
| 2003-12-31 | $225.21 Million | -9.82% |
| 2002-12-31 | $249.73 Million | -5.89% |
| 2001-12-31 | $265.36 Million | +0.47% |
| 2000-12-31 | $264.13 Million | +411.87% |
| 1999-12-31 | $51.60 Million | +1.78% |
| 1998-12-31 | $50.70 Million | -5.06% |
| 1997-12-31 | $53.40 Million | +146.08% |
| 1996-12-31 | $21.70 Million | +97.27% |
| 1995-12-31 | $11.00 Million | +134.04% |
| 1994-12-31 | $4.70 Million | +213.33% |
| 1993-12-31 | $1.50 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more